During his five years of doctoral training, he worked on the identification of early diagnostic/ prognostic markers and identification and characterization of biomarkers as surrogate end points in clinical trials for advanced Head and Neck Cancer. His doctoral work facilitated the identification of early diagnostic/prognostic markers using the in vitro models and patient samples, which lead to a robust biomarker panel for oral carcinogenesis. He was also involved in several other projects related to breast and esophageal cancer during his doctoral studies.

At University of Texas MD Anderson Cancer Center, USA, he was extensively involved in high end proteomic analysis to identify the novel mechanisms and signalling alterations associated with drug resistance in cancer cells using in vitro and in vivo models. He has also continued his effort for identification of biomarkers for early diagnosis/prognosis of cancer. His studies have revealed that the dysregulated immunoproteasome complex in lung cancer is responsible for immune escape and this phenomenon is related to epithelial and mesenchymal transition (EMT) which increases cell proliferation and survival of cancer cells. He also discovered that the hybrid phenotype of EMT is more stable and is highly invasive as well as aggressive compared to mesenchymal cells. He also actively participated in similar studies related to ovarian, breast, pancreatic and prostate cancer. His work has received recognition and has been greatly appreciated at various international conferences. Over all, with years of research experience, he has pioneered the proteomics related studies and data analysis and is confident that his studies will help in understanding the mechanism needed to eradicate cancer.